Compare Main Street Capital Corporation (MAIN) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Main Street Capital Corporation vs Natera Inc. Common Stock — how do they compare? Main Street Capital Corporation trades at $53.66 (market cap $5.03B), while Natera Inc. Common Stock trades at $393.27 (market cap $57.03B). The key difference: Natera Inc. Common Stock is far larger — about 11.3× Main Street Capital Corporation's market cap, and Main Street Capital Corporation pays a 5.91% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Main Street Capital Corporation for 89 Days and Natera Inc. Common Stock for 0 Days on average.
| MAIN | NTRA | |
|---|---|---|
Market Cap | $5.03B | $57.03B |
Volume | 386,945 | 1,131,157 |
Sector | Financials | Health |
52-Week High | $64.60 | $425.64 |
52-Week Low | $49.63 | $179.42 |
Typical Hold Time | 89 Days | 0 Days |
Enterprise Value | $7.48B | $56.18B |
Dividend Yield | 5.91% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MAIN trades at $53.50, down 0.3% on the day, with a bearish technical signal and key support at $53. The stock shows strong profitability with an 80.77% net margin and a P/E of 10.8, but revenue declined slightly in 2025 to $592M. Recent quarterly earnings have been mixed, beating in Q2 2026 but missing in Q1. The company maintains a consistent dividend, with recent payments of $0.27-$0.30 per share.
The outlook is cautious; while MAIN's high margins and dividend yield near 7.9% appeal to income investors, bearish technicals, softening revenue, and a high proportion of analyst 'Hold' ratings suggest limited near-term upside. Risks include earnings volatility and sensitivity to interest rates, but the stock trades below the consensus price target of $58, offering potential appreciation if fundamentals stabilize.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Main Street Capital Corporation
Main Street Capital Corp is an investment firm engaged in providing customized debt and equity financing to lower middle market companies and debt capital to middle market companies. The investment portfolio of the company is typically made to support management buyouts, recapitalizations, growth financings, refinancings and acquisitions of companies that operate in diverse industry sectors. The group invests in secured debt investments, equity investments, warrants and other securities of the lower middle market and middle market companies based in the US. Business is functioned through the U.S region and it derives the majority of the income from the source of fee, commission, and interest.
Read more on MAIN →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
